FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03792-8
Abstract: BackgroundFLAG (fludarabine, cytarabine, granulocyte colony—stimulating factor) and FLAG-IDA (idarubicin added to standard FLAG) are salvage chemotherapy regimens used for relapsed and refractory acute leukemias. The toxicity of the FLAG-IDA courses is generally more severe than… read more here.
Keywords: relapsed refractory; flag ida; refractory acute; remission ... See more keywords
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-018-0283-5
Abstract: The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML)… read more here.
Keywords: refractory aml; hematology; flag ida; study ... See more keywords
Frontline Sequential Allogeneic Stem Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia with 3q26.2/Mecom Rearrangement
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-208585
Abstract: BACKGROUND Acute myeloid leukemia with 3q26.2/MECOM rearrangement (MECOMr AML) is a rare entity with very poor prognosis due to the low efficacy of standard treatments. Allogeneic stem cell transplantation (alloSCT) remains the only curative or… read more here.
Keywords: allosct; stem cell; flag ida; ida ven ... See more keywords
High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1666
Abstract: Background: Despite significant advances in treatment of AML over the past decade, long-term survival remains poor. The addition of venetoclax (Ven) to intensive chemotherapy backbones has been evaluated in multiple early-phase clinical trials demonstrating high… read more here.
Keywords: flag ida; risk; response; ida ven ... See more keywords
FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5152
Abstract: Background: The FLAG-IDA (fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor, and idarubicin) regimen is rarely used as frontline induction therapy for pediatric patients with de novo acute myeloid leukemia (AML). Therefore, this study aimed to assess… read more here.
Keywords: frontline induction; flag ida; pediatric patients; kmt2a rearranged ... See more keywords
A Multicenter Nonrandom Clinical Study of Induction Regimen of FLAG-ID and Dae in the Treatment of Childhood De Novo Acute Myeloid Leukemia in South of China:the Early Report of Efficacy and Safety
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3873.3873
Abstract: Objective: Complete remission (CR) after induction chemotherapy was one of the important prognostic factors in the treatment of acute myeloid leukemia(AML). Intensive induction regimen have potential of increasing the CR rate, but also followed high… read more here.
Keywords: flag ida; induction; treatment; group ... See more keywords
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.24.00259
Abstract: PURPOSE To evaluate the survival benefit of chemotherapy intensification in older patients with AML who have not achieved a measurable residual disease (MRD)–negative remission. METHODS Five hundred twenty-three patients with AML (median age, 67 years;… read more here.
Keywords: patients aml; flag ida; older patients; intensification ... See more keywords